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Sir,
We wish to address the recent proposal of a disease entity
newly titled ‘limbic-predominant age-related TDP-43 ence-
phalopathy (LATE)’ (Nelson et al., 2019) which, to our
reading, is itself a derivative of the 2016 proposed term
cerebral age-related TDP-43 with sclerosis (CART)
(Nelson et al., 2016). The transactive response DNA
binding protein of 43 kD (TDP-43) was ﬁrst reported
in 2006 to be a main component of ubiquitinated inclu-
sions in autopsy-conﬁrmed cases of frontotemporal lobar
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degeneration (FTLD) negative for tau immunoreactivity
(Arai et al., 2006; Neumann et al., 2006). Over a decade
of research into FTLD-TDP (and FTLD-U before it) has
highlighted important phenotypic variability in TDP-43-
immunoreactive lesions resulting in the identiﬁcation of
ﬁve different types of FTLD-TDP (Mackenzie et al., 2006,
2011; Sampathu et al., 2006; Josephs et al., 2009; Lee
et al., 2011, 2017). There have also been important
advances in the molecular and biochemical characterization
of TDP-immunoreactive in FTLD-TDP (Sampathu et al.,
2006; Hasegawa et al., 2008; Igaz et al., 2008; Zhang
et al., 2009; Bigio et al., 2013; Laferriere et al., 2019).
Soon after the initial characterization of TDP-immunoreac-
tive lesions in FTLD and amyotrophic lateral sclerosis,
TDP-immunoreactive lesions were identiﬁed in 25–33%
of cases with pathologically conﬁrmed Alzheimer’s disease
(Amador-Ortiz et al., 2007; Higashi et al., 2007). TDP-
immunoreactive lesions related to Alzheimer’s disease
were initially thought to appear ﬁrst in the hippocampus
(Amador-Ortiz et al., 2007), but more detailed morpholo-
gical studies involving multiple anatomical regions revealed
the amygdala to be the earliest affected region (Higashi
et al., 2007; Hu et al., 2008; Arai et al., 2009) followed
by the entorhinal cortex and hippocampus, occipitotem-
poral cortex, insular and inferior temporal cortex, brain-
stem, and frontal neocortex and basal ganglia (Josephs
et al., 2014, 2016); a scheme that has been independently
validated (Tan et al., 2015). TDP-immunoreactive lesions
have also been described in cognitively normal individuals
(Wilson et al., 2011; Arnold et al., 2013; Uchino et al.,
2015; Wennberg et al., 2019) including those with asymp-
tomatic deﬁnite primary age related tauopathy (PART)
(Josephs et al., 2017; Zhang et al., 2019), as well being
associated with other well-deﬁned clinic-pathological enti-
ties (Fig. 1) including Lewy body disease (with or without
co-existing Alzheimer’s disease) (Arai et al., 2009;
McAleese et al., 2017), the amyotrophic lateral sclerosis/
parkinsonism-dementia complex of Guam (Hasegawa
et al., 2007; Geser et al., 2008), Pick’s disease (Freeman
et al., 2008), progressive supranuclear palsy (Yokota et al.,
2010; Koga et al., 2017), corticobasal degeneration (Uryu
et al., 2008; Koga et al., 2018), polyglutamine diseases
such as Huntington’s disease (Schwab et al., 2008),
Machado-Joseph disease (Tan et al., 2009) and spinocere-
bellar ataxia type 2 (Toyoshima et al., 2011), Perry syn-
drome (Wider et al., 2009), and chronic traumatic
encephalopathy (McKee et al., 2010).
The term LATE is proposed as a catchy acronym to
describe the presence of TDP-immunoreactive lesions in
Alzheimer’s disease, as well as in older adults. The review
manuscript describing LATE, of which many of the authors
of this response are cited in, provides a thorough appraisal
of an important topic and is meritorious in promoting
recognition of TDP-43 and encouraging future research,
as well as the development of neuroimaging and molecular
biomarkers. However, we question the term’s novelty and
nosology, the framework that seemingly separates LATE
from FTLD-TDP and other diseases, and the proposed
guidelines provided for assessing LATE and LATE-NC.
As the authors identify, the term LATE is new, although
there is an extensive literature on the relationship between
TDP-immunoreactive inclusions and clinical and imaging
features, both in isolation and in association with
Alzheimer’s disease. LATE is used to rebrand already char-
acterized features, yet identiﬁes no new TDP-43 pathologi-
cal subtype, no link between TDP-immunoreactive
pathology with new cognitive symptoms (other than like-
lihood of dementia diagnosis) according to known brain–
behaviour relationship, and no biochemical demonstration
that TDP-immunoreactive lesions in older adults with and
without Alzheimer’s disease are equivalent to each other or
distinct from those in FTLD-TDP and other neurodegen-
erative diseases. Critically, using the term encephalopathy
(‘E’ of LATE) presumes causation of functional impairment
Figure 1 TDP-43 immunoreactive inclusions can be found in many different neurodegenerative diseases. Currently TDP-43
proteinopathies are divided into primary TDP-43 proteinopathies and mixed (secondary) TDP-43 proteinopathies. AD = Alzheimer’s disease;
ALS = amyotrophic lateral sclerosis; CBD = corticobasal degeneration; CTE = chronic traumatic encephalopathy; FTLD = frontotemporal lobar
degeneration; LBD = Lewy body disease; PART = primary age related tauopathy; PDC = Parkinson-dementia complex; PSP = progressive supra-
nuclear palsy; SCA = spinocerebellar ataxia.
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in the cerebrum and by incorporating the term encephalo-
pathy, LATE implies a clinicopathological entity, when in
reality LATE is only describing the pathology LATE-NC;
similar to pathologies such as argyrophilic grains disease
(Braak and Braak, 1987), primary age-related tauopathy
(Crary et al., 2014), ageing-related tau astrogliopathy
(Kovacs et al., 2016) and amygdala Lewy bodies
(Uchikado et al., 2006), which are not considered clinico-
pathological entities. Akin to the dichotomy of language
between frontotemporal dementia and FTLD, LATE is
something that, by deﬁnition, cannot be diagnosed under
the microscope (i.e. encephalopathy). And as these lesions
can be observed in the absence of cognitive alterations,
rendering a diagnosis of an encephalopathy in a cognitively
normal individual is an oxymoron (normal cognition with
limbic associated TDP-43 encephalopathy).
Proposing that LATE is a distinct clinicopathological
entity also overlooks the possibility that TDP-immunoreac-
tive lesions in Alzheimer’s disease could reﬂect impaired
cellular function in end-stage neurodegeneration, and
ignores the fact that the statistical association between
TDP-immunoreactive pathology and a dementia diagnosis
in old age is likely both not independent from Alzheimer’s
disease and other pathologies, and, in all likelihood, a
reﬂection of competing relative risks of various degrees as
one ages. In addition, the term limbic-predominant is an
over simpliﬁcation of the distribution of pathology. In fact,
it has been demonstrated that there are different subtypes
of TDP immunoreactivity that have different regional asso-
ciations, with only one speciﬁc subtype of neuroﬁbrillary
tangle-associated TDP proving to be truly limbic-predomi-
nant (Amador-Ortiz et al., 2007; Josephs et al., 2019;
Zhang et al., 2019). The other subtype is associated with
TDP-43 involving cortical and subcortical and brainstem
regions identical to those affected in FTLD-TDP (Josephs
et al., 2019). This is akin to Lewy body disease, which can
also have a limbic-predominance, but to label it as such
would ignore the brainstem and diffuse distributions of
the pathology. Different subtypes of TDP-immunoreactive
also have different genetic and pathological associations,
including with hippocampal sclerosis; important differences
that would be lost when grouping subtypes together
(Murray et al., 2014; Josephs et al., 2019).
Third, this paper does not consider how LATE can be
distinguished from FTLD-TDP or the fact that LATE
depends on a relative selection bias towards Alzheimer’s
disease-related diseases while ignoring the fact that TDP-
43 has been identiﬁed in many other neurodegenerative
diseases (Fig. 1) making teasing apart coincident versus
associated processes a challenge. Of importance is the fact
that a proportion of cases of Alzheimer’s disease and
ageing have TDP-immunoreactive lesions present in fronto-
temporal neocortex (Arai et al., 2009; Josephs et al., 2014,
2016; Nag et al., 2018). It has been shown that such cases
are strongly associated with single nucleotide polymorph-
isms in the TMEM106B gene (Josephs et al., 2019), which
is similar to the observed associations in FTLD-TDP (Van
Deerlin et al., 2010). It is, therefore, unclear whether it is
appropriate to make a diagnosis of LATE in the presence of
a TDP-43 stage 43 (Josephs et al., 2014, 2016), as
opposed to a diagnosis of FTLD-TDP. The description of
LATE also does not square with evidence that FTLD-TDP
can occur in old age (Jellinger, 2006; Pao et al., 2011), and
that age itself may modify the clinical phenomenology of
neuropathology due to the brain’s structural and functional
reorganization.
The authors provide guidelines on how to assess LATE-
NC neuropathologically and suggest analysing a few speci-
ﬁc regions of the brain with the intent to have a limited
number of TDP-43 stages. While this simpliﬁes neuro-
pathological analysis and is touted as being cost effective,
it collapses data-driven staging schemes but without the
requisite scientiﬁc evidence for doing so. This proposal mir-
rors the NIA-AA neuropathological guidelines for the
pathological diagnosis of Alzheimer’s disease, which col-
lapse the Braak (Braak and Braak, 1991), Thal (Thal
et al., 2002) and CERAD (Mirra et al., 1991) staging
schemes. However, collapsing the TDP-43 staging scheme
at such an early point in time when it was only published
in the past few years, stiﬂes the ﬁelds ability to understand
the implications of the distribution of TDP-43 deposition
and goes against the drive by many neuropathologists to
include more comprehensive and quantitative assessment
methods to unravel currently hidden relationships of
pathologies.
The branding of clinical trials since the 1990s—especially
names such as EPIC or EXCITE—is said to promote refer-
ence to such trials (Berkwits, 2000), but can compete with
the understanding of the main message (Berlin, 2013;
Narod et al., 2016; Witteman et al., 2018). Whether an
acronym such is LATE is needed for diagnostic accuracy
and communication between neuropathologists, neurolo-
gists, and other investigators is not clear. Therefore, we
urge researchers to focus on deﬁning the pathological pro-
cesses and their biochemical differences underlying TDP-
immunoreactive lesions in FTLD and non-FTLD disorders,
particularly in diverse populations, and defer broad usage
of LATE until (and only if) the science is mature.
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